Meta tags:

Headings (most frequently used words):

the, 2014, deals, friday, in, of, february, blog, week, tuesday, 07, march, this, is, biotech, to, private, pages, subscribe, follow, us, headlines, from, pink, sheet, daily, contributors, labels, april, 2015, 04, 28, 21, 14, about, click, these, links, archive, footer, vivo, no, more, takes, stock, what, buoyant, ipo, scene, doing, trends, fotf, says, not, much, stakeholders, consumer, genomics, read, dotw, keeps, tabs, as, tax, trimming, fuels, novartis, places, bid, dominate, cancer, financings, fortnight, and, neverending, venture, round, ucsf, catalyzes, tech, transfer, with, sector,

Text of the page (most frequently used words):
the (538), and (284), for (132), with (112), that (109), its (99), million (72), deal (60), has (58), will (56), company (52), from (50), this (44), are (44), but (42), tax (41), have (36), which (35), also (35), #biotech (33), cash (30), development (29), said (29), phase (29), research (28), was (28), year (28), drug (27), last (27), two (27), new (27), one (26), companies (26), more (24), than (23), pharmaceuticals (23), pharma (22), february (21), into (21), years (21), stock (21), 2013 (20), series (20), march (19), about (19), cancer (19), now (19), based (19), their (19), program (18), not (18), while (18), billion (18), ipo (18), rate (18), since (17), shares (17), actavis (17), all (16), feb (16), clinical (16), disease (16), most (16), deals (16), week (16), patients (16), public (16), well (16), were (16), forest (16), 2014 (15), january (15), 2012 (15), according (15), programs (15), they (15), products (15), price (15), fda (15), round (15), merck (15), may (14), could (14), those (14), been (14), other (14), first (14), firm (14), after (14), anti (14), data (14), start (13), recent (13), university (13), life (13), our (13), share (13), investors (13), had (13), led (13), there (13), just (13), rights (12), november (12), therapeutics (12), sciences (12), preclinical (12), pfizer (12), drugs (12), only (12), candidate (12), lead (12), including (12), biopharma (12), novimmune (12), novartis (12), october (11), 2011 (11), these (11), discovery (11), industry (11), ucsf (11), product (11), both (11), even (11), out (11), some (11), can (11), work (11), announced (11), what (11), offering (11), biotechs (11), over (11), december (10), comments (10), immunotherapy (10), private (10), early (10), oncology (10), each (10), capital (10), effective (10), upfront (10), regulatory (10), like (10), develop (10), antibody (10), venture (10), developer (10), much (10), trials (10), synthetic (10), vivo (9), april (9), june (9), july (9), september (9), blog (9), strategic (9), medical (9), take (9), partnership (9), stage (9), through (9), them (9), three (9), option (9), focus (9), when (9), candidates (9), inhibitor (9), cell (9), trial (9), paid (9), raised (9), ceo (9), investor (9), iii (9), gilead (9), cart (9), you (9), biology (9), biogen (9), business (8), report (8), transactions (8), labels (8), diseases (8), medimmune (8), might (8), move (8), institute (8), small (8), end (8), assets (8), technology (8), very (8), terms (8), five (8), sales (8), acquisition (8), platform (8), average (8), undisclosed (8), partners (8), rounds (8), fund (8), around (8), compound (8), completed (8), thanks (8), money (8), would (8), corporate (8), selling (8), arrowhead (8), big (8), cells (8), discuva (8), eye (8), august (7), database (7), financing (7), collaboration (7), between (7), who (7), should (7), disorders (7), making (7), disclosed (7), funding (7), activity (7), good (7), specialty (7), expected (7), shareholders (7), per (7), immune (7), under (7), therapies (7), top (7), purchase (7), bacterial (7), infections (7), month (7), time (7), long (7), treatment (7), didn (7), here (7), four (7), down (7), few (7), before (7), study (7), off (7), argos (7), milestones (7), another (7), servier (7), targets (7), latest (7), use (7), ireland (7), taxes (7), among (7), irish (7), issues (7), roche (7), consumer (7), eisai (7), 2015 (6), via (6), pain (6), astrazeneca (6), joseph (6), haas (6), provide (6), expertise (6), advanced (6), science (6), benefits (6), areas (6), large (6), primary (6), head (6), lot (6), six (6), rest (6), cadence (6), says (6), additional (6), treat (6), roughly (6), pierre (6), whose (6), novel (6), space (6), due (6), young (6), york (6), includes (6), clinic (6), ventures (6), market (6), initial (6), genetic (6), founded (6), fortnight (6), amanda (6), micklus (6), ago (6), doesn (6), partner (6), past (6), find (6), buy (6), non (6), still (6), pronutria (6), during (6), sellers (6), protein (6), already (6), using (6), elan (6), abide (6), andromeda (6), genomics (6), harvard (6), value (6), 2006 (5), 2007 (5), 2010 (5), tech (5), rare (5), mergers (5), acquisitions (5), california (5), san (5), help (5), projects (5), working (5), different (5), inflammation (5), post (5), potential (5), along (5), signed (5), way (5), agreement (5), read (5), mallinckrodt (5), existing (5), keep (5), acquire (5), management (5), group (5), day (5), fabre (5), growth (5), payments (5), include (5), retrophin (5), portfolio (5), revenue (5), debiopharm (5), affinium (5), antibiotics (5), pathway (5), field (5), paul (5), bonanos (5), back (5), recently (5), least (5), decade (5), create (5), equity (5), same (5), 100 (5), total (5), his (5), focused (5), several (5), therapy (5), late (5), gram (5), negative (5), follow (5), worth (5), closed (5), second (5), license (5), laboratories (5), high (5), financial (5), such (5), paladin (5), celgene (5), rbc (5), inc (5), genomic (5), ariad (5), ridaforolimus (5), alzheimer (5), facebook (5), genocea (5), neostem (5), 2009 (4), pink (4), sheet (4), marketing (4), subscribe (4), academia (4), catalyst (4), diagnostics (4), broad (4), metabolic (4), autoimmune (4), any (4), support (4), yao (4), case (4), next (4), multiple (4), options (4), better (4), biotechnology (4), area (4), sanofi (4), make (4), times (4), third (4), hospital (4), major (4), transaction (4), device (4), approved (4), severe (4), net (4), included (4), pay (4), held (4), return (4), french (4), checkpoint (4), aurigene (4), peptide (4), associated (4), part (4), pharmaceutical (4), receive (4), commercial (4), line (4), profitable (4), compounds (4), particularly (4), acid (4), intellectual (4), swiss (4), antibiotic (4), acquired (4), created (4), staphylococcus (4), resistant (4), expects (4), entered (4), fall (4), aveo (4), nda (4), filed (4), exit (4), commons (4), photo (4), complete (4), founder (4), commercialization (4), stacy (4), lawrence (4), friday (4), spin (4), rnai (4), juno (4), later (4), largest (4), barbut (4), kind (4), name (4), monoclonal (4), commercialize (4), hot (4), range (4), rather (4), underwriters (4), priced (4), many (4), studies (4), dollars (4), get (4), against (4), chris (4), less (4), mass (4), specific (4), compared (4), launch (4), perhaps (4), atlas (4), lisa (4), lamotta (4), target (4), treatments (4), multi (4), biological (4), costim (4), being (4), where (4), center (4), become (4), inked (4), asset (4), inhaled (4), massachusetts (4), mit (4), systems (4), genome (4), rapidly (4), endo (4), idec (4), unknown (4), strategies (4), low (4), front (4), prior (4), gaap (4), income (4), related (4), school (4), partnered (4), safety (4), patient (4), note (4), acadia (4), neurocrine (4), johnson (4), 000 (4), hli (4), prices (4), pharmas (4), ear (4), information (3), com (3), daily (3), home (3), email (3), translational (3), francisco (3), advantage (3), stages (3), awards (3), academic (3), advisors (3), review (3), select (3), further (3), health (3), lee (3), started (3), represent (3), sectors (3), cardiovascular (3), respiratory (3), infectious (3), people (3), bring (3), really (3), look (3), technologies (3), unit (3), feature (3), overall (3), want (3), give (3), developing (3), therapeutic (3), forward (3), months (3), access (3), told (3), licensing (3), plans (3), full (3), trading (3), volume (3), valuation (3), bought (3), split (3), modulator (3), efficacy (3), used (3), combination (3), tumor (3), payment (3), manchester (3), close (3), risk (3), approval (3), spectrum (3), afn (3), weren (3), type (3), known (3), shown (3), aureus (3), oral (3), aiming (3), preserve (3), resistance (3), astellas (3), renal (3), tivozanib (3), worldwide (3), kinase (3), indication (3), decided (3), response (3), key (3), john (3), paying (3), property (3), sector (3), fotf (3), financings (3), antibodies (3), huge (3), giant (3), chf (3), board (3), wrote (3), know (3), went (3), found (3), took (3), began (3), building (3), abbvie (3), too (3), course (3), term (3), days (3), markets (3), every (3), bump (3), column (3), melinta (3), vatera (3), testing (3), single (3), play (3), mid (3), point (3), proposed (3), ended (3), reach (3), reports (3), hiv (3), survival (3), changing (3), grossed (3), land (3), genzyme (3), noting (3), having (3), revealed (3), flagship (3), connelly (3), half (3), own (3), going (3), endocrine (3), direct (3), israeli (3), flickr (3), creative (3), fopo (3), best (3), alex (3), lash (3), reported (3), labs (3), attention (3), amount (3), mpm (3), indications (3), antigen (3), receptor (3), global (3), leukemia (3), inhibitors (3), house (3), then (3), heard (3), strategy (3), currently (3), action (3), news (3), cellectis (3), original (3), usual (3), upon (3), curx (3), tobramycin (3), endpoint (3), quarter (3), details (3), press (3), release (3), engineering (3), craig (3), wendy (3), diller (3), pseudomonas (3), aeruginosa (3), valeant (3), results (3), tecfidera (3), credits (3), prothena (3), merrion (3), alkermes (3), alexion (3), rates (3), derived (3), delivery (3), becoming (3), federal (3), social (3), cardinal (3), agonist (3), uses (3), potentially (3), double (3), proprietary (3), diapep277 (3), teva (3), human (3), proceeds (3), placebo (3), 23andme (3), mark (3), ratner (3), personal (3), considers (3), why (3), commission (3), instead (3), optionality (3), psychosis (3), aquinox (3), aqx (3), 1125 (3), ship1 (3), venter (3), list (3), stem (3), lean (3), don (3), bigger (3), whatsapp (3), ever (3), favor (3), beta (3), amyloid (3), dana (3), farber (3), schepens (3), informa (2), www (2), pharmamedtechbi (2), plc (2), medicine (2), 2008 (2), devices (2), click (2), join (2), posts (2), transfer (2), neither (2), biologics (2), somewhat (2), unique (2), intended (2), input (2), advance (2), increased (2), ctsi (2), researchers (2), director (2), 120 (2), growing (2), mostly (2), various (2), her (2), plan (2), molecule (2), added (2), faculty (2), whom (2), doing (2), accounting (2), she (2), goal (2), enable (2), things (2), appropriate (2), outside (2), determine (2), licensed (2), senior (2), innovative (2), johns (2), hopkins (2), maryland (2), baltimore (2), arrangements (2), allocation (2), basis (2), noted (2), backing (2), local (2), base (2), advances (2), meanwhile (2), founding (2), underway (2), within (2), genentech (2), parkinson (2), heating (2), snowy (2), winter (2), intravenous (2), gives (2), addition (2), sell (2), supply (2), ofirmev (2), moderate (2), opioid (2), revenues (2), premium (2), weighted (2), cosmetics (2), almost (2), india (2), aunp (2), indian (2), fewer (2), effects (2), levels (2), models (2), milestone (2), others (2), either (2), progresses (2), concert (2), chenodeoxycholic (2), indicated (2), essential (2), hypertension (2), uncomplicated (2), cases (2), seek (2), chenodal (2), iia (2), 1720 (2), class (2), promise (2), methicillin (2), care (2), companion (2), struck (2), carcinoma (2), japanese (2), except (2), factor (2), reception (2), left (2), terminated (2), terminating (2), studying (2), wikimedia (2), credit (2), letter (2), netted (2), davis (2), jessica (2), merrill (2), launched (2), outs (2), commitment (2), bezos (2), eight (2), extensions (2), 200 (2), tranche (2), makes (2), reached (2), open (2), structure (2), common (2), expect (2), see (2), gone (2), main (2), peer (2), smaller (2), longer (2), example (2), raising (2), change (2), raise (2), nearly (2), spent (2), waiting (2), exercise (2), 0501 (2), orphan (2), status (2), pediatric (2), biggest (2), got (2), wholly (2), owned (2), seems (2), attract (2), investment (2), offer (2), behind (2), without (2), rib (2), until (2), traditionally (2), failed (2), try (2), set (2), mary (2), delafloxacin (2), finance (2), acute (2), skin (2), address (2), targeting (2), site (2), right (2), likes (2), beyond (2), onto (2), fourth (2), yet (2), overallotment (2), knowing (2), although (2), 2016 (2), likely (2), virus (2), piece (2), sold (2), plus (2), macrogenics (2), ptc (2), remaining (2), isn (2), driving (2), helped (2), hard (2), cap (2), table (2), robert (2), entities (2), individuals (2), supplied (2), remainder (2), muscle (2), strength (2), formulations (2), amino (2), similar (2), possibly (2), requirements (2), cystic (2), fibrosis (2), trying (2), nasdaq (2), notes (2), publicly (2), highlights (2), unveiled (2), team (2), entire (2), outright (2), spec (2), generics (2), receiving (2), closely (2), significant (2), portion (2), targeted (2), annually (2), pipelines (2), solid (2), revealing (2), actually (2), cambridge (2), done (2), carl (2), chronic (2), leukemias (2), facility (2), augment (2), couple (2), comes (2), bristol (2), myers (2), squibb (2), combo (2), starting (2), showed (2), getting (2), presence (2), north (2), american (2), activist (2), measures (2), flipped (2), taking (2), cd19 (2), pipeline (2), hdac (2), molecules (2), initially (2), fact (2), core (2), fosfomycin (2), subsequently (2), mrsa (2), infected (2), collaborating (2), tools (2), involves (2), current (2), bioinformatics (2), parts (2), short (2), scratch (2), scientific (2), synberc (2), millions (2), netting (2), ability (2), opportunity (2), generation (2), warner (2), chilcott (2), locked (2), patent (2), sovaldi (2), perrigo (2), pretty (2), lowest (2), mean (2), lower (2), buying (2), locales (2), moving (2), newest (2), twist (2), leverage (2), higher (2), reduced (2), independent (2), garnered (2), highest (2), larger (2), percentage (2), profits (2), coming (2), remain (2), singapore (2), efforts (2), merger (2), always (2), hasn (2), slowed (2), countries (2), respectively (2), ernst (2), dataset (2), professor (2), dotw (2), world (2), ezekowitz (2), entrepreneur (2), became (2), immunology (2), former (2), diabetes (2), selective (2), identify (2), organization (2), directed (2), important (2), pathogens (2), meeting (2), digit (2), wave (2), aim (2), previously (2), call (2), iclusig (2), maintenance (2), limited (2), free (2), future (2), media (2), number (2), however (2), continue (2), control (2), successful (2), dtc (2), commentaries (2), how (2), legal (2), ethical (2), come (2), draft (2), authors (2), analyze (2), available (2), originally (2), presidential (2), bioethical (2), tuesday (2), values (2), quite (2), bit (2), pre (2), step (2), ups (2), multiples (2), enough (2), choices (2), your (2), pimavanserin (2), antagonist (2), clinically (2), diego (2), neurological (2), 98854 (2), strong (2), slightly (2), apiece (2), jefferies (2), morgan (2), corp (2), investments (2), enzyme (2), discovered (2), system (2), securities (2), macular (2), momentum (2), project (2), aging (2), holdings (2), soon (2), biosciences (2), despite (2), plenty (2), grab (2), translate (2), ones (2), true (2), buyouts (2), ideas (2), tend (2), retention (2), bonuses (2), reveals (2), balance (2), far (2), mega (2), paper (2), component (2), buyout (2), ragosa (2), released (2), bace (2), sponsor (2), michael (2), vsels (2), trudeau (2), rss (2), skip (2), reserved, copyright, footer, 329, 484, 436, 261, 193, 112, 108, archive, conferences, today, rpm, links, welcome, commentary, developments, biopharmaceutical, policy, discussion, contact, atom, older, arm, nor, stranger, external, basic, burgeoning, given, resources, oversees, digital, applications, explained, 140, numbers, folks, disciplines, happy, coincidence, spurred, considering, neuroscience, bringing, 400, 300, primarily, docs, graduate, students, necessary, though, spurring, purpose, portal, ready, tie, medicines, imed, bing, unlike, determined, facilitate, extends, extend, personnel, staff, exclusive, backs, gaithersburg, shored, signing, relationships, gets, technological, stemming, hub, bay, members, international, negotiated, collaborations, bayer, stromedix, uniqure, cold, projected, sole, acetaminophen, setting, generic, medications, capabilities, covidien, mild, adjunctive, analgesics, reduction, fever, 110, twice, posted, sept, fidelity, rowe, associates, wellington, vanguard, nea, blackrock, trailing, 250, equally, skincare, excluding, say, greater, side, achieves, subcutaneous, dosing, inhibited, metastasis, bangalore, collaborated, inception, 2002, progress, middle, specializes, alone, marketed, vinflunine, vinorelbine, generates, collaborators, arranged, privately, focuses, collins, colo, suffering, gallstones, surgery, poses, unacceptable, age, mecamylamine, hci, tablets, moderately, malignant, quick, cerebrotendinous, xanthomatosis, ctx, disorder, cause, disability, prove, fatal, guided, anticipates, broadened, toronto, narrow, fabi, 1252, prodrug, arrangement, inhibit, fatty, synthesis, fas, combating, vancomycin, intermedia, allowing, switching, leaving, diagnostic, tcg, gut, flora, overcoming, genesys, oxford, bioscience, ontario, emerging, pegged, cover, expenses, asia, manufacture, tyrosine, vascular, endothelial, receptors, unenthusiastic, advisory, committee, expecting, rcc, breast, colorectal, cancers, calls, reasons, crc, aug, 125, acquiring, vecamyl, navelbine, javlor, death, spun, encoding, organ, failure, serve, clearinghouse, consortium, pact, catalyzes, nutritionals, insane, sums, infectives, friends, reeled, buzz, venrock, expeditions, aka, amazon, chief, jeff, stash, raw, coinage, hold, candle, novi, stands, boosted, london, specialists, rosetta, jonathan, hepple, joining, extension, jack, kept, fairness, easy, employees, sweat, preferred, liquidation, thus, comply, statutes, stringent, equal, 2000, carry, precedent, extended, handful, topped, sangart, shut, symphogen, hurry, charts, length, none, blockbuster, secure, theraclone, spaltudaq, applaud, brought, endocyte, alvine, does, sort, liquidity, event, nearer, finding, 0101, tlr4, interferon, gamma, solo, hemophagocytic, lymphohistiocytosis, deadly, seem, cushioned, dilutive, date, outlicensing, il17, financials, tier, runway, welcomed, stripe, platforms, heavily, capitalized, plays, inevitable, ask, cards, played, mind, banks, nice, ride, traditional, escalator, forced, fist, maureen, riordan, did, scenes, healthcare, falcon, flight, affiliate, santo, domingo, backers, named, housecleaning, szela, differentiated, flouroquinolone, dose, gonorrhea, filing, selection, seeking, serious, threatening, binding, ribosome, yes, command, above, mere, launching, increase, dilution, word, largely, treaded, water, solace, bargain, ipos, performers, discounted, legs, notable, boost, iib, ags, 004, interruption, aids, game, eradication, adults, aims, ambitious, eliminate, reduce, negligible, 104, ironwood, puma, inclusion, unthinkable, bumping, microcap, strictly, conjugate, doubt, rna, interference, riding, revival, sorts, highlighted, alnylam, agenda, hedge, propel, spring, recapped, pushing, hepatitis, owner, turnover, wasn, bloodbath, longtime, anzalone, helm, remains, unnamed, participating, alongside, provided, family, offices, venturelabs, quietly, period, lifting, lid, probably, final, protecting, frail, elderly, sarcopenia, loss, occur, periods, hospitalization, 107, 365, leucine, delivered, shot, sized, beverages, bottled, energy, supermarket, shelves, pharmacokinetics, balances, acids, deciding, nutritional, supplements, foods, scheduled, completion, mulling, parallel, addressing, gastrointestinal, beneficial, chemotherapy, whatever, develops, reside, separate, ease, eventual, concurrently, dependence, registered, gain, ataluren, duchenne, muscular, dystrophy, caused, nonsense, mutations, wake, ema, chmp, opinion, maa, hedging, bets, float, manages, patents, royalty, courtesy, mike, mantin, 261m, convertible, pdl, mediwound, bio, blast, galmed, 126m, 60m, biodelivery, bunavail, 55m, versartis, colleagues, dicerna, monthwith, explored, dramatically, cut, executive, hasraised, pool, celiac, fierce, notched, examined, fates, somewhere, neverending, certainly, expansion, branded, implications, pick, nabbed, beginning, force, red, managing, directors, luke, evnin, millman, joined, bruce, booth, contingent, viii, knows, thing, imatinib, earliest, dollar, 2003, boasts, richest, spanning, numerous, liquid, hottest, foray, chimeric, enriched, upped, dominant, player, cagey, bill, brings, hearing, strengths, attacking, admitted, pennsylvania, lab, express, fusion, consisting, attach, commonly, expressed, lymphocytic, cll, mediated, genetically, engineered, injected, expressing, kill, pairing, penn, internally, opening, scale, manufacturing, morristown, dramatic, everybody, room, looking, immunotherapies, smokin, glanced, analysts, trusted, jumping, bandwagon, incyte, amgen, combine, 3475, respective, employing, hoping, explore, tumors, thought, immunosuppressant, revolutionary, memorial, sloan, kettering, adult, lymphoblastic, achieved, remission, modified, profile, car, below, unrecognizable, little, icelandic, merged, behemoth, multinational, continuing, road, transformation, turn, brand, boosting, combined, comprise, standalone, represents, closing, ideal, icahn, brent, saunders, touted, magic, touch, architect, sale, 840, tied, success, ucart19, rival, complement, immunotherapeutic, antiangiogenic, proapoptotic, jean, abastado, lymphomas, hands, plotting, domination, hcv, busy, script, calling, lung, infection, met, discontinued, aztreonam, pathogenic, bacteria, enhance, covers, investigators, scientists, definitions, essentially, integrating, codes, ultimate, techniques, design, construction, professional, discipline, taken, national, foundation, funded, creation, participants, berkeley, stanford, nsf, awarded, organizations, centers, ventor, climbing, visible, practitioners, intrexon, 171, programmable, presents, processes, cellular, expression, jose, carlos, gutierrez, ramos, biotherapeutics, reaching, inflection, accelerate, improve, biotherapeutic, tobi, cayston, wants, bausch, lomb, watson, dispute, gleevec, places, bid, dominate, fares, stopped, push, ramp, inversions, merge, country, consolidation, frenzy, driven, jurisdictions, wins, earns, books, gobble, competitors, thereby, margins, obvious, winner, astonishing, lowered, apply, encompass, newly, floundering, aren, routes, roads, locale, biopharmas, count, themselves, lucky, teens, 20s, anticipated, dimethyl, fumarate, sofosbuvir, domiciled, effort, curb, expenditures, solution, level, decline, following, beefed, operations, vialing, eculizumab, resulted, whopping, translated

Text of the page (random words):
cuva the latest including a pair of preclinical deals and another two that were called off in this week s edition of celgene abide celgene likes to keep all its options open to acquire companies to acquire programs and to license programs in its latest r d deal with the preclinical abide therapeutics disclosed on feb 28 it included an option to purchase its biotech partner as well as an option to license the rest of the world rights on the first two programs to reach the clinic abide s most advanced compound ab101131 is expected to enter the clinic in 2015 the biotech expects to get three or four additional candidates into the clinic under the collaboration its technology selectively targets serine hydrolases to develop new treatments for inflammation and immunological disorders founded in 2011 abide was seeded by venture firm cardinal partners celgene and cardinal partners both participated in an undisclosed equity financing concurrent with the deal other terms of the deal including the upfront also remain undisclosed abide is headed by alan ezekowitz an entrepreneur in residence at cardinal partners who became the biotech s president ceo and co founder prior to that he was at merck research laboratories the research division of merck co inc as svp and franchise head of bone respiratory immunology and endocrine abide s platform is based on work by professors ben cravatt and dale boger of the scripps research institute the biotech secured its first big biopharma deal last may it partnered with ezekowitz former employer merck in that deal it garnered an undisclosed upfront and milestones of up to 430 million to discover develop and commercialize small molecules against three novel targets to treat metabolic diseases with a focus on type ii diabetes in the last few years celgene has done at least three prior deals that included an option to purchase the company an october 2013 deal with cancer and fibrotic disease company pharmakea therapeutics a july 2013 partnership with toll like receptor agonist developer ventirx pharmaceuticals and an october 2012 deal with selective small molecule histone deacetylase hdac inhibitor developer acetylon pharmaceuticals stacy lawrence roche discuva roche and u k biotech discuva are collaborating on the discovery and development of new antibiotics to treat multi drug resistant gram negative infections using discuva s selective antibiotic target identification technology platform sati uses next generation sequencing and bioinformatics to identify bacterial targets and select from among them promising drug development candidates the deal announced on feb 28 fits well with roche s revamped research strategy in infectious diseases a field its r d organization exited more than 20 years ago but recently has re entered the new narrower focus is on multi drug resistant pathogen specific hospital directed therapies rather than broad spectrum antibiotics that were roche s original focus companion diagnostics an area of strength due to roche s long experience in molecular diagnostics will be important in identifying pathogens in an october 2013 meeting in new york roche s head of research and early stage development john reed outlined his organization s priorities noting that the antibiotics field is attractive now in part because the animal models are good in the clinical context and the regulatory path is clearer particularly for safety requirements thanks to recent fda guidance discuva will receive an upfront payment of 16 million as well as research fees and payments on multiple programs of up to 175 million per product upon achievement of certain development commercial and sales milestones it will also receive potentially double digit royalties on product sales discuva uses proprietary methods built from recent genomic discoveries to identify targets that affect bacterial growth and viability as well as related genes potentially associated with development of downstream resistance the problem of multi drug resistance to gram negative infections is growing but has not received as much attention as gram positive infections gram negative pathogens addressed by discuva include pseudomonas aeruginosa acinetobacter baumannii klebsiella pneumonia escherichia coli and neisseria gonorrhoeae the company was founded in early 2012 with backing from new wave ventures new wave s co founder tim bullock is chairman of discuva s board the amount his firm contributed to the start up is not public david williams is an entrepreneur who founded sareum a u k oncology biotech that went public on aim and previously worked at millennium pharmaceuticals acambis and medivir wendy diller merck ariad the fate of ariad pharmaceuticals mtor inhibitor ridaforolimus is uncertain now that pharma partner merck co has decided to return rights to the cancer drug ariad revealed in its year end financial release feb 25 that merck is terminating a licensing agreement for the development and commercialization of ridaforolimus effective in november the move creates a new clinical and business opportunity for ariad the company said in a statement but management didn t even mention ridaforolimus during a same day conference call ariad is focused on the re launch of iclusig ponatinib which re entered the u s market in january for the treatment of leukemia after sales were temporarily halted last year due to safety concerns the company is also running clinical trials to meet fda s post marketing commitments for iclusig and to expand its label to new indications merck s decision to end the agreement shouldn t surprise investors especially now that the big pharma s oncology focus has shifted to its pd 1 immunotherapy program ridaforolimus was rejected by fda in 2012 as a maintenance treatment for sarcoma after it failed to demonstrate a benefit on survival in a phase iii trial and only a limited two week progression free survival advantage under the original 2007 collaboration between the two companies merck paid 75 million upfront for development and commercialization rights to ridaforolimus and agreed to pay up to 452 million in development milestones and 200 million in r d payments the deal was revised in 2010 to give merck global rights rather than a u s profit split merck paid out some 222 5 million in upfront and milestone payments during the life of the deal according to the strategic transactions database jessica merrill teva andromeda in a case of a no deal possibly leading to another deal andromeda biotech reacquired rights to type 1 diabetes candidate diapep277 along with equity from fellow israeli company teva to undo the firms 2007 partnership around the human heat shock protein 60 hsp 60 derived peptide andromeda will pay teva total consideration of approximately 72 million in future installments based upon revenues or proceeds payable to its shareholders that unraveling of a deal on feb 24 was followed by media reports feb 26 that clal biotechnology another israeli company which owns 96 of andromeda was working on selling andromeda and the diapep277 program to an undisclosed u s biopharma for a price that might number in the hundreds of millions of dollars at press time however a second transaction could not be confirmed andromeda said it will continue a 475 patient confirmatory phase iii trial for the candidate the 24 month double blind placebo controlled trial is being conducted at more than 100 locations in north america europe israel and argentina patient recruitment was completed in september 2012 and the trial is expected to produce data by the end of this year the trial is studying diapep277 s ability to preserve the patient s insulin secretion by the pancreas with a primary endpoint of maintenance of glycemic control joseph haas thanks to 401 k 2013 from flickr for the use of the image which we find both alarming and strangely beautiful by unknown at 6 24 pm 0 comments labels actavis alexion alkermes biogen idec celgene corporate tax elan endo gilead ireland merrion paladin perrigo prothena sovaldi tax credits tecfidera friday february 21 2014 deals of the week novartis places bid to dominate in cancer while the largest deal of the week and certainly the one receiving the most attention has been actavis expansion of its branded portfolio via its 25 billion purchase of forest laboratories the deal that could have major implications for a hot target space in cancer is novartis pick up of a small massachusetts biotech novartis nabbed young start up costim pharmaceuticals at the beginning of the week for an undisclosed amount a move that could make it a major force in the red hot area of cancer immunotherapy the closely held biotech was founded in 2012 by mpm capital and led by mpm managing directors luke evnin and robert millman atlas ventures joined mpm in early 2013 to fund the company s 10 million series a round while terms of the deal were not disclosed atlas partner bruce booth wrote in a recent blog post that if the contingent milestones are paid this deal will return a significant portion of the entire life science allocation in atlas fund viii the swiss pharma knows a thing or two about oncology it s been marketing gleevec imatinib one of the earliest targeted cancer treatments and a multi billion dollar drug annually since 2003 and it boasts one of the richest oncology pipelines in the industry spanning numerous solid and liquid tumor indications and many of the hottest biological targets its latest r d foray into chimeric antigen receptor technology cart and the programs it s acquired from costim has enriched the pharma s immunotherapy platform and upped its commitment to being a dominant player in oncology while novartis has been cagey about revealing what costim actually has to offer bill sellers its global head of oncology says the cambridge biotech brings four to five late stage programs to the table programs the industry could start hearing about in early 2015 one of our strengths is attacking cancer from its genetic base said sellers but we have not done a lot of work in immunotherapy until two years ago he admitted that s when novartis inked its deal with the university of pennsylvania for its cart research the deal is based on the work of carl june whose lab created t cells that express the receptor cart 19 a synthetic fusion protein consisting of antibodies that attach to the cd 19 protein commonly expressed in chronic lymphocytic cll and other b cell mediated leukemias the genetically engineered t cells are injected back into the patients where they find their way to cd 19 expressing leukemia cells and kill them since pairing up with penn novartis has been building expertise internally said sellers as well as opening a large scale manufacturing facility in morristown nj cart has shown dramatic efficacy but it doesn t work in everybody said sellers so there is room to augment that sellers said novartis has been looking for a way to get into checkpoint inhibitors and other immunotherapies for a couple of years knowing it doesn t have the expertise in house that s where costim comes in one of its late stage assets targets the pd 1 pathway the smokin hot pd 1 pathway if you ve paid any attention to or even just glanced at companies like merck or bristol myers squibb in recent months then you ve heard about their anti pd 1 drugs combination therapies with these checkpoint inhibitors are going to be huge 35 billion huge if some analysts are to be trusted merck already is jumping on the combo bandwagon it s inked three deals with pfizer incyte and amgen just this month to combine its anti pd 1 checkpoint inhibitor mk 3475 with assets in their respective pipelines novartis is employing a different strategy it s hoping to move forward with a cart pd 1 combo we are just starting to explore cart in solid tumors which are thought to be more immunosuppressant said sellers cart programs may be just as revolutionary as pd 1 on feb 19 memorial sloan kettering cancer center announced results from a trial of adult b cell acute lymphoblastic leukemia that showed 88 of patients achieved complete remission after receiving the modified t cells the technology is the basis for the founding of high profile start up juno therapeutics which currently is locked in a patent dispute over the car technology with novartis french biotech servier also is getting in on the action as you can read below in actavis forest actavis is nearly unrecognizable from the little icelandic company it was just three years ago the company has merged with both warner chilcott plc and watson pharmaceuticals during that time to become a generics behemoth with multinational presence now it is continuing down the road of transformation with its 25 billion acquisition of forest laboratories the stock and cash deal will turn actavis into a developer of specialty brand name drugs boosting specialty products to represent about 50 of combined company revenue north american specialty pharmaceuticals currently comprise about 30 of actavis standalone revenue forest shareholders will get 26 04 in cash and a portion of an actavis share for each forest share the total per share price of 89 48 represents a premium of about 25 over forest s closing price on feb 14 the last trading day before the deal was announced of 71 39 for forest this is an ideal exit for its shareholders activist investor carl icahn has said in news reports that this acquisition is a good example of when activist measures work forest ceo brent saunders has been touted as having the magic touch he flipped forest in less than six months after taking over and was the architect behind the sale of bausch lomb to valeant pharmaceuticals for 8 7 billion before that lisa lamotta servier cellectis servier wants a piece of the cart action the french biotech inked a collaboration with cell therapy company cellectis on feb 17 for 10 million upfront and 840 million in potential milestones tied to the development regulatory and commercial success of six potential products the deal includes the development of ucart19 cellectis lead product a cd19 targeting compound that is in early stages but could be a potential rival to novartis lead cart program which also targets the cd19 t cells these original cell based therapies will well complement servier s innovative clinical oncology pipeline which currently includes immunotherapeutic monoclonal antibodies an hdac inhibitor kinase inhibitors antiangiogenic and proapoptotic small molecules said jean pierre abastado head of oncology at servier the deal initially will focus on leukemias and lymphomas with servier having the option to license the products and take over development after phase i has been completed l l gilead curx gilead sciences has had its hands full what with plotting the domination of the market for all oral hcv treatment so busy in fact that the biotech has signed only one r d deal in almost the last two years a preclinical partnership with a...